Rogers & Wells partner Kevin Arquit is a man who might know a thing or twoabout ghosts.
Seven years ago, as the zealous director of the Federal Trade Commission’sBureau of Competition, Arquit helped conjure up a novel legal stratagem.Now, as the zealous lead counsel for generic drug maker Mylan LaboratoriesInc., he has found his past returning to haunt him. Citing Arquit’shandiwork, the FTC is trying to collect $120 million from his client in asuit filed in D.C. federal court.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]